

WHAT IS CLAIMED IS

1. Use of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety, in the manufacture of a medicament for the treatment of a disease associated with fibrosis selected from non-alcoholic steatohepatitis (NASH), liver fibrosis, or cirrhosis.
2. The use of claim 1, wherein said disease associated with fibrosis is NASH.
3. Use of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety, in the manufacture of a medicament for the treatment or prevention of NASH.
4. The use of claim 1, wherein said disease associated with fibrosis is cirrhosis.
5. The use of claim 1, wherein said disease associated with fibrosis is liver fibrosis.
6. The use of any one of claims 1-5, wherein said poly(ethylene glycol) has a molecular weight of about 30 kDa.
7. The use of any one of claims 1-6, which results in one or more of decreased hepatic fat fraction and increased adiponectin levels in said patient.
8. The use of any one of claims 1-7, wherein said medicament is to be administered by subcutaneous injection.
9. The use of any one of claims 1-8, wherein said medicament is to be administered at a dosage of said modified FGF-21 polypeptide of between about 0.05 mg/kg and about 1 mg/kg of patient body weight.
10. Use of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety having a molecular weight of about 30 kDa for the manufacture of a medicament for treating NASH, wherein said medicament is to be administered by subcutaneous

injection in a dosage of modified FGF-21 polypeptide of between about 0.05 mg/kg and about 1 mg/kg of patient body weight at a frequency of about once per week.

11. Use of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety having a molecular weight of about 30 kDa for the manufacture of a medicament for treating NASH, wherein said medicament is to be administered by subcutaneous injection in a dosage of modified FGF-21 polypeptide of about 20 mg at a frequency of about once per week.
12. The use of claim 10 or 11, wherein said poly(ethylene glycol) moiety has a molecular weight of 30 kDa.
13. The use of any one of claims 1-12, wherein said para-acetyl-phenylalanine residue is linked to said poly(ethylene glycol) moiety by an oxime linkage, wherein said oxime linkage has the structure resulting from the reaction of a carbonyl group and aminoxy group.